Advertisement

Neuro-ophthalmology Approach to Oculoplastic Disorders

  • Tiffany Kent
  • James Banks ShepherdIII
  • Gregory P. Van StavernEmail author
Chapter

Abstract

Neuro-ophthalmologists often participate in the care of patients with oculoplastic disorders. Their role may be the initial diagnosis, with subsequent referral; managing a patient ultimately found to have a neurologic reason for the oculoplastic condition (e.g., a patient with ptosis found to be secondary to myasthenia gravis); or coordinated care of diseases which straddle both specialties (e.g., thyroid orbitopathy, chronic progressive external ophthalmoplegia, skull base tumors, orbital inflammatory syndrome, etc.). As with all of medical practice, good communication is an essential foundation for a fruitful and successful partnership in the care of patients.

Keywords

Cavernous Sinus Progressive Supranuclear Palsy Myotonic Dystrophy Nephrogenic Systemic Fibrosis Oculomotor Nerve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Brazis PW. General principles. In: Brazis PW, Masdeu JC, Biller J, editors. Localization in clinical neurology. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006. p. 1–24.Google Scholar
  2. 2.
    Breasted J. The Edwin Smith surgical papyrus. Chicago: Chicago University Press; 1930.Google Scholar
  3. 3.
    Berker EA, Berker AH, Smith A. Translation of Broca’s 1865 report. Localization of speech in the third left frontal convolution. Arch Neurol. 1986;43:1065–1072.PubMedGoogle Scholar
  4. 4.
    Wilson-Pauwels L, Akesson EJ, Stewart PA. Sandoz course. Cranial nerve: anatomy and clinical comments. Philadelphia: B.C. Decker; 1988.Google Scholar
  5. 5.
    Elstein AS, Shulman LS, Sprafka SA. Medical problem solving: an analysis of clinical reasoning. Cambridge, MA: Harvard University Press; 1978. p. 64–66.Google Scholar
  6. 6.
    Wigton RS. Use of linear models to analyse physicians’ decisions. Med Decis Making. 1988;8:241–252.PubMedGoogle Scholar
  7. 7.
    Eva KW. What every teacher needs to know about clinical reasoning. Med Edu. 2004;39:98–106.Google Scholar
  8. 8.
    Norman G, Young M, Brooks L. Non-analytical models of clinical reasoning: the role of experience. Med Edu. 2007;41:1140–1145.Google Scholar
  9. 9.
    Graber M, Gordon R, Franklin N. Reducing diagnostic errors in medicine: what’s the goal? Acad Med. 2002;77:981–992.PubMedGoogle Scholar
  10. 10.
    Croskerry P. The importance of cognitive errors in diagnosis and the strategies to minimize them. Acad Med. 2003;78:775–780.PubMedGoogle Scholar
  11. 11.
    Norman GR, Eva KW. Diagnostic error and clinical reasoning. Med Edu. 2010;44:94–100.Google Scholar
  12. 12.
    Bose S. Neuroimaging in neuro-ophthalmology. Neurosurg Focus. 2007;23:1–9.Google Scholar
  13. 13.
    Lekwuwa GU, Barnes GR. Cerebral control of eye movements. Brain. 1996;119:473–490.PubMedGoogle Scholar
  14. 14.
    Averbuch-Heller L, Leigh RJ, Mermelstein V, Zagalsky L, et al. Ptosis in patients with hemispheric strokes. Neurology. 2002;58:620–624.PubMedGoogle Scholar
  15. 15.
    Van Stavern GP. Efferent: supranuclear motility Continuum lifelong learning. Neurology. 2009;15(4):127–148.Google Scholar
  16. 16.
    Biousse V, Skibell BC, Watts RL, Loupe DN, et al. Ophthalmologic features of Parkinson’s disease. Neurology. 2004;62:177–180.PubMedGoogle Scholar
  17. 17.
    Lepore FE, Devoisin RC. “Apraxia” of eyelid opening: an involuntary levator inhibition. Neurology. 1985;35:423–427.PubMedGoogle Scholar
  18. 18.
    Pelak VS, Hall DA. Neuro-ophthalmologic manifestations of neurodegenerative disease. Ophthalmol Clin North Am. 2004;17:311–320.PubMedGoogle Scholar
  19. 19.
    Altiparmak U, Eggenberger E, Coleman A, Condon K. The ratio of square wave jerk rates to blink rates distinguishes progressive supranuclear palsy from Parkinson’s disease. J Neuroophthalmol. 2006;26:257–259.PubMedGoogle Scholar
  20. 20.
    Kerrison JB, Newman NJ. Five things oculoplastic surgeons should know about neuro-ophthalmology. Ophthal Plast Reconstr Surg. 1999;15(6):373–7.PubMedGoogle Scholar
  21. 21.
    Cogan DG. Internuclear ophthalmoplegia: typical and atypical. Arch Ophthalmol. 1970;84:583–589.PubMedGoogle Scholar
  22. 22.
    Keane JR. Ocular skew deviation. Analysis of 100 cases. Arch Neurol. 1975;32:185–190.PubMedGoogle Scholar
  23. 23.
    Dieterich M, Brandt T. Ocular torsion and tilt of subjective visual vertical are sensitive brainstem signs. Ann Neurol. 1993;33:292–299.PubMedGoogle Scholar
  24. 24.
    Frohman LP, Kupersmith MJ. Reversible vertical ocular deviations associated with raised intracranial pressure. J Clin Neuroophthalmol. 1985;5:158–163.PubMedGoogle Scholar
  25. 25.
    Haines DE, Lancon JA. Neuroanatomy, North American edition: an Atlas of structures, sections, and systems. 7th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007.Google Scholar
  26. 26.
    Biousse V, Newman NJ. Neuro-ophthalmology illustrated. 1st ed. New York: Thieme Medical Publishers; 2009.Google Scholar
  27. 27.
    Miller NR, Newman NJ. Walsh and Hoyt’s clinical neuro-ophthalmology. 6th ed. Philadelphia: Lippincott, Williams & Wilkins; 2004.Google Scholar
  28. 28.
    Bruce BB, Biousse V, Newman NJ. Third nerve palsies. Semin Neurol. 2007;27(3):257–268.PubMedGoogle Scholar
  29. 29.
    Trobe JD. Rapid diagnosis in Ophthalmology series: Neuro-Ophthalmology. 1st ed. Mosby 2007.Google Scholar
  30. 30.
    Brazis PW. Isolated palsies of cranial nerves III, IV, and VI. Semin Neurol. 2009;29(1):14–28.PubMedGoogle Scholar
  31. 31.
    Brazis PW. Palsies of the trochlear nerve: diagnosis and localization–recent concepts. Mayo Clin Proc. 1993;68(5):501–9.PubMedGoogle Scholar
  32. 32.
    Carpenter MB, Batton RR. Abducens internuclear neurons and their role in conjugate horizontal gaze. J Comp Neurol. 1980;189:191–209.PubMedGoogle Scholar
  33. 33.
    Gradenigo G. A special syndrome of endocranial otitic complications (paralysis of the motor oculi externus of otitic origin). Ann Otol Rhinol Laryngol. 1904;13:637.Google Scholar
  34. 34.
    Rambo JH, Petti GH. Petrous apicitis. AMA Arch Otolaryngol. 1957;65(5):523–4.PubMedGoogle Scholar
  35. 35.
    DeGraaf J, Cats H, de Jager AEJ. Gradenigo’s syndrome: a rare complication of otitis media. Clin Neurol Neurosurg. 1988;90:237–239.Google Scholar
  36. 36.
    Miller RW, Lee AG, Schiffman JS, et al. A practice pathway for the initial diagnostic evaluation of isolated sixth cranial nerve palsies. Med Decis Making. 1999;19:42–48.PubMedGoogle Scholar
  37. 37.
    Sanders SK, Kawasaki A, Purvin VA. Long-term prognosis in patients with vasculopathic sixth nerve palsy. Am J Ophthalmol. 2002;134:81–84.PubMedGoogle Scholar
  38. 38.
    Lee MS, Galetta SL, Volpe NJ, Liu GT. Sixth nerve palsies in children. Pediatr Neurol. 1999;20:49–52.PubMedGoogle Scholar
  39. 39.
    Keane JR. Cavernous sinus syndrome. Analysis of 151 cases. Arch Neurol. 1996;53:967–71.PubMedGoogle Scholar
  40. 40.
    Colnaghi S, Versino M, Marchioni E, et al. ICHD-II diagnostic criteria for Tolosa-Hunt syndrome in idiopathic inflammatory syndromes of the orbit and/or the cavernous sinus. Cephalalgia. 2008;28:577.PubMedGoogle Scholar
  41. 41.
    Kline LB, Hoyt WF. The Tolosa-Hunt syndrome. J Neurol Neurosurg Psychiatry. 2001;71(5):577–82.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Areaya AA, Cerezal L, Canga A, et al. Neuroimaging diagnosis of Tolosa-Hunt syndrome: MRI contribution. Headache. 1999;39(5):321–325.Google Scholar
  43. 43.
    Evans OB, Lexow SS. Painful ophthalmoplegia in systemic lupus erythematosus. Ann Neurol. 1978;4:584–585.PubMedGoogle Scholar
  44. 44.
    Miller NR. Diagnosis and management of dural carotid-cavernous sinus fistulas. Neurosurg Focus. 2007;23(5):E13.PubMedGoogle Scholar
  45. 45.
    Yeh S, Foroozan R. Orbital apex syndrome. Curr Opin Ophthal. 2004;15:490–498.Google Scholar
  46. 46.
    Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–69.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7:365–368.PubMedGoogle Scholar
  48. 48.
    Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126:2304–2311.PubMedGoogle Scholar
  49. 49.
    Haven TR, Astill ME, Pasi BM, et al. An algorithm for acetylcholine receptor antibody testing in patients with suspected myasthenia gravis. Clin Chem. 2010;56:1028–1029.PubMedGoogle Scholar
  50. 50.
    Cruz AA, Akaishi PM, Vargas MA, de Paula SA. Association between thyroid autoimmune dysfunction and non-thyroid autoimmune diseases. Ophthal Plast Reconstr Surg. 2007;23:104–108.PubMedGoogle Scholar
  51. 51.
    Tellez-Zenteno JF, Cardenas G, Estanol B, Garcia-Ramos G, Weder-Cisneros N. Associated conditions in myasthenia gravis: response to thymectomy. Eur J Neurol. 2004;11:767–773.PubMedGoogle Scholar
  52. 52.
    Tellez-Zenteno JF, Remes-Troche JM, Mimenza-Alvarado A, Garcia-Ramos G, Estanol B, Vega-Boada F. The association of myasthenia gravis and connective tissue diseases. Effects of thymectomy in six cases with rheumatoid arthritis and one case with systemic lupus erythematosus. Neurologia. 2003;18:54–58.PubMedGoogle Scholar
  53. 53.
    Christensen PB, Jensen TS, Tsiropoulos I, et al. Associated autoimmune diseases in myasthenia gravis. A population-based study. Acta Neurol Scand. 1995;91:192–195.PubMedGoogle Scholar
  54. 54.
    Thorlacius S, Aarli JA, Riise T, Matre R, Johnsen HJ. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand. 1989;80:290–295.PubMedGoogle Scholar
  55. 55.
    Monden Y, Uyama T, Nakahara K, et al. Clinical characteristics and prognosis of myasthenia gravis with other autoimmune diseases. Ann Thorac Surg. 1986;41:189–192.PubMedGoogle Scholar
  56. 56.
    Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893–902.PubMedGoogle Scholar
  57. 57.
    Yu CC, Chen SG, Chen TM. Frontalis slings with palmaris tendon as an adjuvant treatment for myasthenic blepharoptosis: a case report. Ann Plast Surg. 2007;58:577–579.PubMedGoogle Scholar
  58. 58.
    Lelli Jr GJ, Musch DC, Frueh BR, Nelson CC. Outcomes in silicone rod frontalis suspension surgery for high-risk noncongenital blepharoptosis. Ophthal Plast Reconstr Surg. 2009;25:361–365.PubMedGoogle Scholar
  59. 59.
    Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2002;73:766–768.PubMedCentralPubMedGoogle Scholar
  60. 60.
    Cruciger MP, Brown B, Denys EH, et al. Clinical and subclinical oculomotor findings in the Eaton-Lambert syndrome. J Clin Neuroophthalmol. 1983;3:19–22.PubMedGoogle Scholar
  61. 61.
    O’Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577–596.PubMedGoogle Scholar
  62. 62.
    Breen LA, Gutmann L, Brick JF, Riggs JR. Paradoxical lid elevation with sustained upgaze: a sign of Lambert-Eaton syndrome. Muscle Nerve. 1991;14:863–866.PubMedGoogle Scholar
  63. 63.
    Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26:4276–4281.PubMedGoogle Scholar
  64. 64.
    Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995;58:85–87.PubMedCentralPubMedGoogle Scholar
  65. 65.
    Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70:924–928.PubMedGoogle Scholar
  66. 66.
    Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology. 2002;59:1773–1775.PubMedGoogle Scholar
  67. 67.
    Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2003;CD003279.Google Scholar
  68. 68.
    Krieger FT, Goldchmit M. Surgical correction of strabismus in Lambert-Eaton myasthenic syndrome: case reports. Arq Bras Oftalmol. 2009;72:99–102.PubMedGoogle Scholar
  69. 69.
    Villar RG, Shapiro RL, Busto S, et al. Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina. JAMA. 1999;281:1334–1338, 1340.PubMedGoogle Scholar
  70. 70.
    Townes JM, Cieslak PR, Hatheway CL, et al. An outbreak of type A botulism associated with a commercial cheese sauce. Ann Intern Med. 1996;125:558–563.PubMedGoogle Scholar
  71. 71.
    Kongsaengdao S, Samintarapanya K, Rusmeechan S, et al. An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure. Clin Infect Dis. 2006;43:1247–1256.PubMedGoogle Scholar
  72. 72.
    Dowell Jr VR, McCroskey LM, Hatheway CL, Lombard GL, Hughes JM, Merson MH. Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulism. JAMA. 1977;238:1829–1832.PubMedGoogle Scholar
  73. 73.
    Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA. 1997;278:433–435.PubMedGoogle Scholar
  74. 74.
    Lamantea E, Tiranti V, Bordoni A, et al. Mutations of mitochondrial DNA polymerase gamma are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia. Ann Neurol. 2002;52:211–219.PubMedGoogle Scholar
  75. 75.
    Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet. 2001;28:211–212.PubMedGoogle Scholar
  76. 76.
    Fratter C, Gorman GS, Stewart JD, et al. The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology. 2010;74:1619–1626.PubMedCentralPubMedGoogle Scholar
  77. 77.
    Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science. 2000;289:782–785.PubMedGoogle Scholar
  78. 78.
    Schoser BG, Pongratz D. Extraocular mitochondrial myopathies and their differential diagnoses. Strabismus. 2006;14:107–113.PubMedGoogle Scholar
  79. 79.
    Almousa R, Charlton A, Rajesh ST, Sundar G, Amrith S. Optimizing muscle biopsy for the diagnosis of mitochondrial myopathy. Ophthal Plast Reconstr Surg. 2009;25:366–370.PubMedGoogle Scholar
  80. 80.
    Harding AE, Hammans SR. Deletions of the mitochondrial genome. J Inherit Metab Dis. 1992;15:480–486.PubMedGoogle Scholar
  81. 81.
    Drachman DA. Ophthalmoplegia plus. The neurodegenerative disorders associated with progressive external ophthalmoplegia. Arch Neurol. 1968;18:654–674.PubMedGoogle Scholar
  82. 82.
    Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histologic study in one of two cases. AMA Arch Ophthalmol. 1958;60:280–289.PubMedGoogle Scholar
  83. 83.
    Berenberg RA, Pellock JM, DiMauro S, et al. Lumping or splitting? “Ophthalmoplegia-plus” or Kearns-Sayre syndrome? Ann Neurol. 1977;1:37–54.PubMedGoogle Scholar
  84. 84.
    Lopez-Gallardo E, Lopez-Perez MJ, Montoya J, Ruiz-Pesini E. CPEO and KSS differ in the percentage and location of the mtDNA deletion. Mitochondrion. 2009;9:314–317.PubMedGoogle Scholar
  85. 85.
    Ogasahara S, Yorifuji S, Nishikawa Y, et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology. 1985;35:372–377.PubMedGoogle Scholar
  86. 86.
    Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2006;CD004426.Google Scholar
  87. 87.
    Fang W, Huang CC, Lee CC, Cheng SY, Pang CY, Wei YH. Ophthalmologic manifestations in MELAS syndrome. Arch Neurol. 1993;50:977–980.PubMedGoogle Scholar
  88. 88.
    Hsu CC, Chuang YH, Tsai JL, et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand. 1995;92:252–255.PubMedGoogle Scholar
  89. 89.
    Hirano M, Ricci E, Koenigsberger MR, et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord. 1992;2:125–135.PubMedGoogle Scholar
  90. 90.
    Thambisetty M, Newman NJ. Diagnosis and management of MELAS. Expert Rev Mol Diagn. 2004;4:631–644.PubMedGoogle Scholar
  91. 91.
    Lane CM, Collin JR. Treatment of ptosis in chronic progressive external ophthalmoplegia. Br J Ophthalmol. 1987;71:290–294.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Daut PM, Steinemann TL, Westfall CT. Chronic exposure keratopathy complicating surgical correction of ptosis in patients with chronic progressive external ophthalmoplegia. Am J Ophthalmol. 2000;130:519–521.PubMedGoogle Scholar
  93. 93.
    Wong VA, Beckingsale PS, Oley CA, Sullivan TJ. Management of myogenic ptosis. Ophthalmology. 2002;109:1023–1031.PubMedGoogle Scholar
  94. 94.
    Johnson CC, Kuwabara T. Oculopharyngeal muscular dystrophy. Am J Ophthalmol. 1974;77:872–879.PubMedGoogle Scholar
  95. 95.
    Esmaeli B, Chung H, Pashby RC. Long-term results of frontalis suspension using irradiated, banked fascia lata. Ophthal Plast Reconstr Surg. 1998;14:159–163.PubMedGoogle Scholar
  96. 96.
    Salvi SM, Currie ZI. Frontalis suspension sling using palmaris longus tendon in chronic progressive external ophthalmoplegia. Ophthal Plast Reconstr Surg. 2009;25:140–141.PubMedGoogle Scholar
  97. 97.
    Soejima K, Sakurai H, Nozaki M, et al. Surgical treatment of blepharoptosis caused by chronic progressive external ophthalmoplegia. Ann Plast Surg. 2006;56:439–442.PubMedGoogle Scholar
  98. 98.
    Bernardini FP, de Conciliis C, Devoto MH. Frontalis suspension sling using a silicone rod in patients affected by myogenic blepharoptosis. Orbit. 2002;21:195–198.PubMedGoogle Scholar
  99. 99.
    Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;69:385.PubMedGoogle Scholar
  100. 100.
    Feyma T, Carter GT, Weiss MD. Myotonic dystrophy type 1 coexisting with myasthenia gravis and thymoma. Muscle Nerve. 2008;38:916–920.PubMedGoogle Scholar
  101. 101.
    Burian HM, Burns CA. Ocular changes in myotonic dystrophy. Trans Am Ophthalmol Soc. 1966;64:250–273.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Waller RR. Management of myogenic (myopathic) ptosis. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1975;79:697–702.PubMedGoogle Scholar
  103. 103.
    Fan X, Rouleau GA. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy. Can J Neurol Sci. 2003;30:8–14.PubMedGoogle Scholar
  104. 104.
    Hebbar S, Webberley MJ, Lunt P, Robinson DO. Siblings with recessive oculopharyngeal muscular dystrophy. Neuromuscul Disord. 2007;17:254–257.PubMedGoogle Scholar
  105. 105.
    Brais B, Bouchard JP, Xie YG, et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet. 1998;18:164–167.PubMedGoogle Scholar
  106. 106.
    Molgat YM, Rodrigue D. Correction of blepharoptosis in oculopharyngeal muscular dystrophy: review of 91 cases. Can J Ophthalmol. 1993;28:11–14.PubMedGoogle Scholar
  107. 107.
    Jordan DR, Addison DJ. Surgical results and pathological findings in the oculopharyngeal dystrophy syndrome. Can J Ophthalmol. 1993;28:15–18.PubMedGoogle Scholar
  108. 108.
    Kang DH, Koo SH, Ahn DS, Park SH, Yoon ES. Correction of blepharoptosis in oculopharyngeal muscular dystrophy. Ann Plast Surg. 2002;49:419–423.PubMedGoogle Scholar
  109. 109.
    Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve. 2006;34:1–15.PubMedGoogle Scholar
  110. 110.
    Longmuir SQ, Mathews KD, Longmuir RA, Joshi V, Olson RJ, Abramoff MD. Retinal arterial but not venous tortuosity correlates with facioscapulohumeral muscular dystrophy severity. J AAPOS. 2010;14:240–243.PubMedGoogle Scholar
  111. 111.
    Rocha CT, Hoffman EP. Limb-girdle and congenital muscular dystrophies: current diagnostics, management, and emerging technologies. Curr Neurol Neurosci Rep. 2010;10:267–276.PubMedGoogle Scholar
  112. 112.
    Flohr TG, Schaller S, Stierstorfer K, Bruder H, Ohnesorge BM, Schoepf UJ. Multi-detector row CT systems and image-reconstruction techniques. Radiology. 2005;235:756–73.PubMedGoogle Scholar
  113. 113.
    Caille JM, et al. Gadolinium as a contrast agent for NMR. Am J Neuroradiol. 1983;4:1041–1042.PubMedGoogle Scholar
  114. 114.
    Haley TJ, Raymond K, Komesu N, Upham HC. Toxicological and pharmacological effects of gadolinium and samarium chlorides. Br J Pharmacol Chemother. 1961;17:526–32.PubMedCentralPubMedGoogle Scholar
  115. 115.
    Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1.PubMedGoogle Scholar
  116. 116.
    Grobner T. Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–1108.PubMedGoogle Scholar
  117. 117.
    Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619–2621.PubMedCentralPubMedGoogle Scholar
  118. 118.
    US Food and Drug Administration, Information for healthcare professionals gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance) Updated 23 May 2007. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142884.htm. Accessed 21 Aug 2010.
  119. 119.
    Martin DR, Kalb B, Salman K, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010;31(2):440–446.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Tiffany Kent
    • 1
  • James Banks ShepherdIII
    • 1
  • Gregory P. Van Stavern
    • 2
    Email author
  1. 1.Department of Ophthalmology, Barnes-Jewish HospitalWashington UniversitySt. LouisUSA
  2. 2.Department of Ophthalmology and Visual Sciences and Neurology, Barnes-Jewish HospitalWashington University School of MedicineSt. LouisUSA

Personalised recommendations